Compare NMFC & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMFC | MLTX |
|---|---|---|
| Founded | 2010 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.8M | 972.7M |
| IPO Year | 2011 | N/A |
| Metric | NMFC | MLTX |
|---|---|---|
| Price | $9.75 | $14.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $10.00 | ★ $36.33 |
| AVG Volume (30 Days) | 513.6K | ★ 2.0M |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | ★ 13.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $340,877,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.73 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.84 | $5.95 |
| 52 Week High | $12.05 | $62.75 |
| Indicator | NMFC | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 57.57 |
| Support Level | $9.53 | $12.48 |
| Resistance Level | $9.80 | $14.11 |
| Average True Range (ATR) | 0.17 | 0.77 |
| MACD | 0.05 | 0.53 |
| Stochastic Oscillator | 93.29 | 86.30 |
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.